dinutuximab

01/01/2023 - "The anti-GD2 antibody dinutuximab beta (Qarziba®) has been added to the present standard of care for patients with high-risk neuroblastoma in Europe based on the positive results obtained in different studies. "
01/01/2016 - "Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival."
01/01/1991 - "In fact, granulocytes were effective in mediating lysis of neuroblastoma cells coated with ch14.18 irrespective of whether they were obtained from normal adults or from neuroblastoma patients."
07/01/2005 - "In order to improve the outcome, passive immunotherapy using human-mouse chimeric monoclonal anti-disialoganglioside GD2 antibody ch14.18 has been evaluated in early phase clinical trials with promising results in progressing stage 4 neuroblastoma patients. "
01/01/2023 - "A dose escalation study was performed to determine in vivo efficacy of IgA3.0 ch14.18 in an intraperitoneal mouse model using 9464D-GD2 neuroblastoma cells as well as in a subcutaneous human xenograft model using IMR32 neuroblastoma cells. "

12/01/2020 - "In vivo, treatment with aNK cells plus dinutuximab prior to resection of the primary tumor was most effective in limiting metastatic disease and prolonging survival. "
01/01/2022 - "Conclusion:131I-GD2-ch14.18 is cleared slowly from blood, not resulting in good tumor-to-background contrast until 2 d after application. "
01/29/2021 - "In summary, our data provide evidence that dinutuximab might be effective in tumors with high GD2 expression. "
01/01/2021 - "Dinutuximab successfully eliminated GD2+ cells and reduced tumor growth in both in vivo models. "
01/01/2021 - "Finally, dinutuximab in combination with activated natural killer cells inhibited tumor growth in a TNBC PDX model and improved overall survival of tumor-bearing mice. "

11/23/2021 - "Dinutuximab targets the disialoganglioside GD2, which is highly expressed on neuroblastoma cells and minimally present on the surface of normal human neurons, peripheral pain fibers, and skin melanocytes. "
07/01/2006 - "Dose-limiting toxicities were severe allergic reactions to both ch14.18 and R24 as well as pain related to ch14.18. "
01/01/2022 - "Lidocaine for dinutuximab-associated pain? "
10/01/2021 - "To reduce pain while maintaining antitumor activity, we have reformatted the approved GD2 antibody ch14.18 into the IgA1 isotype. "
01/01/2020 - "Dinutuximab is a monoclonal antibody with great clinical promise but is limited by side effects such as severe pain. "

12/01/1997 - "These studies have demonstrated the feasibility of concurrent administration of rIL-2 with the mouse/human chimeric ch14.18 mAb. Although the early pilot studies were conducted in patients with bulky disseminated disease, this approach may be more effective in patients with minimal residual disease. "
11/05/1997 - "Our data suggest that a study of ch14.18-IL-2 as an adjuvant treatment in patients with minimal residual disease may be of value."
01/01/2020 - "Dinutuximab has a proven benefit in the eradication of the minimal residual disease in the treatment of neuroblastoma. "
01/01/2021 - "Although outcomes for patients with high-risk neuroblastoma improved after the addition of a chimeric anti-GD2 monoclonal antibody (dinutuximab) as treatment for minimal residual disease, nearly half of these patients die of disease. "

01/01/2020 - "We investigated the retinoblastoma immune microenvironment and the efficacy of the combination of dinutuximab and CD16-expressing NK-92MI (NK-92MIhCD16-GFP) cells on retinoblastoma cells in this study. "
01/01/2020 - "LDH release and apoptosis in retinoblastoma cells caused by NK-92MIhCD16-GFP cells were significantly enhanced by dinutuximab. "
01/01/2020 - "LDH assays and FC were used to detect LDH release and apoptosis in retinoblastoma cells subjected to a combination of dinutuximab and NK-92MIhCD16-GFP cells. "
01/01/2020 - "Finally, the release of perforin-granzyme B and the expression of CD107a in NK-92MIhCD16-GFP cells stimulated by retinoblastoma cells were obviously increased by dinutuximab. "
01/01/2020 - "Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway."